Abstract
4/2007
vol. 109
Case report
Zastosowanie przeciwciał anti-TNFα (infliximab) w leczeniu chorej z oftalmopatią tarczycową
- Department of Clinical Endocrinology , Medical University of Łódź, Poland. Head: Professor Jan Komorowski, MD, PhD
- Department of Clinical Immunoendocrinology , Medical University of Łódź, Poland. Head: Professor Henryk Stępień, MD, PhD
- Department of Clinical Ophthalmology , Medical University of Łódź, Poland. Head: Professor Roman Goś, MD, PhD
- Department of Radiology, Medical University of Łódź, Poland. Head: Professor Ludomir Stefańczyk, MD, PhD
Klinika Oczna 2007, 109 (4): 457-460
Online publish date: 2007/12/20
TNFα (tumor necrosis factor alpha) plays a central role in the development of thyroid associated ophthalmopathy (TAO). We describe and document by ophthalmic (CAS and NO SPECS scales) and radiological (MRI) evaluation a positive effect of anti-TNFα antibody (infliximab) administration on active TAO in a 58 years old woman with Graves’ disease. The single dose of infliximab administration resulted in a dramatic reduction of inflammation studies and improvement of visual function as measured by MRI and CAS and NO SPECS scales, without noticeable short-term side effects. A randomized prospective study is needed to determine whether infliximab proves to be sufficiently effective in reducing the inflammatory symptoms of TAO, and whether it can be administered safely for a prolonged period without side effects.
Keywords
TNFα, anti-TNFα, Graves’ ophthalmopathy
Integrated with
